H.C. Wainwright analyst Edward White views the recent pullback in shares of Spectrum Pharmaceuticals as a buying opportunity. The next big clinical update for poziotinib is expected in the second half of 2018, most likely at the World Conference on Lung Cancer, White tells investors in a research note. He believes the recent stock price weakness is due to some investors believing that something is wrong with the study since data will not be at ASCO. The analyst, however, reiterates that he never expected to see data at ASCO. He continues to believe the MD Anderson study is proceeding as expected and keeps a Buy rating on Spectrum with a $33 price target.